Non-Type 2 and Mixed Inflammation in Chronic Rhinosinusitis and Lower Airway Disease

被引:2
作者
Heffernan, Austin [1 ]
Shafiee, Amir [1 ]
Chan, Teffran [1 ]
Sparanese, Sydney [1 ]
Thamboo, Andrew [1 ,2 ]
机构
[1] Univ British Columbia, Dept Surg, Div Otolaryngol Head & Neck Surg, Vancouver, BC, Canada
[2] Univ British Columbia, Dept Surg, Div Otolaryngol Head & Neck Surg, 2775 Laurel St,4th Floor, Vancouver, BC V5Z 1M9, Canada
关键词
chronic rhinosinusitis; endotypes; mixed inflammation; non-type; 2; inflammation; unified airway disease; NASAL POLYPS; PHENOTYPES; ENDOTYPES; RECURRENT; HETEROGENEITY; CYTOKINES; CELLS;
D O I
10.1002/lary.30992
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
ObjectiveThe aim was to discuss the role of non-type 2 inflammation in patients diagnosed with chronic rhinosinusitis (CRS) and comorbid lower airway disease.Data SourcesMedline, Embase, National Institute for Health and Care Excellence, TRIP Database, ProQuest, Clinicaltrials.gov, Cochrane Central Registry of Controlled Trials, Web of Science, government and health organizations, and graduate-level theses.Review MethodsThis scoping review followed PRISMA-ScR guidelines. Search strategy was peer-reviewed by medical librarians. Studies were included if they utilized airway sampling, non-type 2 cytokines, and patients with CRS and lower airway disease.ResultsTwenty-seven from 7060 articles were included. In patients with CRS and comorbid asthma, aspirin-exacerbated respiratory disease (AERD), and chronic obstructive pulmonary disease (COPD)/bronchiectasis, 60% (n = 12), 33% (n = 2), and 100% (n = 1), respectively, demonstrated mixed or non-type 2 endotypes. Comorbid CRS and asthma produced type 1 (n = 1.5), type 2 (n = 8), type 3 (n = 1), mixed type 1/2 (n = 1), and mixed type 1/2/3 (n = 8.5) endotype shifts. AERD demonstrated type 2 (n = 4), mixed type 2/3 (n = 1), and mixed type 1/2/3 (n = 1) endotype shifts. CRS with COPD or bronchiectasis demonstrated a mixed 1/2 (n = 1) endotype shift.ConclusionType 2 disease has been extensively reviewed due to advent biologics targeting type 2 inflammation, but outcomes may be suboptimal due to the presence of non-type 2 inflammation. A proportion of patients with CRS and comorbid lower airway disease demonstrated mixed and non-type 2 endotype shifts. This emphasizes that patients with unified airway disease may have forms of inflammation beyond classical type 2 disease which could inform biologic development. Laryngoscope, 2023 Chronic rhinosinusitis (sinusitis) is an inflammatory disorder with multiple underlying aberrant inflammatory pathways. Patients with sinusitis and a lower airway disease have mixed inflammation or isolated type 1, 2 or 3 inflammation.image
引用
收藏
页码:1005 / 1013
页数:9
相关论文
共 61 条
  • [1] [Anonymous], OXFORD CTR EVIDENCE
  • [2] [Anonymous], NCT05583227. Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis
  • [3] EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management
    Bachert, Claus
    Han, Joe K.
    Wagenmann, Martin
    Hosemann, Werner
    Lee, Stella E.
    Backer, Vibeke
    Mullol, Joaquim
    Gevaert, Philippe
    Klimek, Ludger
    Prokopakis, Emanuel
    Knill, Andrew
    Cavaliere, Carlo
    Hopkins, Claire
    Hellings, Peter
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (01) : 29 - 36
  • [4] A classification of chronic rhinosinusitis with nasal polyps based on structured histopathology
    Brescia, Giuseppe
    Alessandrini, Lara
    Giacomelli, Luciano
    Parrino, Daniela
    Zanotti, Claudia
    Tealdo, Giulia
    Franz, Leonardo
    Carraro, Valentina
    Barion, Umberto
    Marioni, Gino
    [J]. HISTOPATHOLOGY, 2020, 76 (02) : 296 - 307
  • [5] Elevated mucus interleukin-17A levels are associated with increased prior sinus surgery for chronic rhinosinusitis
    Chapurin, Nikita
    Li, Ping
    Chandra, Rakesh K.
    Turner, Justin H.
    Chowdhury, Naweed I.
    [J]. INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2021, 11 (02) : 120 - 127
  • [6] Nasal interleukin 25 as a novel biomarker for patients with chronic rhinosinusitis with nasal polyps and airway hypersensitiveness A pilot study
    Chen, Fenghong
    Hong, Haiyu
    Sun, Yueqi
    Hu, Xianting
    Zhang, Jia
    Xu, Geng
    Zhao, Weidong
    Li, Huabin
    Shi, Jianbo
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (04) : 310 - +
  • [7] Chriscaden K., WHO RELEASES COUNTRY
  • [8] Neutrophil infiltrates and eosinophil aggregates in chronic rhinosinusitis with nasal polyps and EGPA
    Contro, Giacomo
    Brescia, Giuseppe
    Alessandrini, Lara
    Barion, Umberto
    Padoan, Roberto
    Frigo, Anna Chiara
    Schiavon, Franco
    Marioni, Gino
    [J]. CLINICAL RHEUMATOLOGY, 2021, 40 (05) : 1949 - 1957
  • [9] Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease
    Corey, Kristen B.
    Turner, Justin H.
    Chowdhury, Naweed I.
    Chandra, Rakesh K.
    Li, Ping
    Wu, Pingsheng
    Cahill, Katherine N.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (06) : 1644 - +
  • [10] Ixekizumab for the treatment of psoriasis: up-to-date
    Craig, Sarah
    Warren, Richard B.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (06) : 549 - 557